Healthcare - Wednesday, December 23, 2009 15:09 - 0 Comments

Javelin Pharmaceuticals, Inc. JAV Trading Session 0.76%

Finkelstein Thompson announces the investigation potential claim on behalf of the shareholders of Javelin Pharmaceuticals Inc. arises from the Company’s announcement to its intent to be acquired by the Myriad Pharmaceuticals. Under the terms on the proposed transaction, shareholders of Javelin will receive 0.282 shares of Myriad stock, or approximately $1.50 per share of Javelin stock owned in the transaction with the total value of approximately 96 million U.S. dollars. The investigation will focus on the potential unfairness of the price to the Javelin shareholders and the process by which the Company’s Board of Directors approved the transaction. The price offered to Javelin appears to be lower than the target price set by the analysts of $3.50 per share of javelin stock.

Last Trade: 1.31
Trade Time: 9:47am ET
Change: Down 0.01 (0.76%)
Prev Close: 1.32
Open: 1.33
Day’s Range: 1.31 – 1.33
52wk Range: 0.91 – 2.28
Volume: 8,320
Avg Vol (3m): 570,366
Market Cap: 83.66M

About Javelin Pharmaceuticals, Inc.

Javelin Pharmaceuticals, Inc. (Javelin) is a specialty pharmaceutical company that applies technologies to develop new products and improved formulations of existing drugs that target medical need in the pain management market. The Company’s product candidates are focused on treating an array of pain disorders ranging from acute and episodic moderate-to-severe pain associated with cancer pain, post-operative pain, post-trauma pain, such as orthopedic injury pain, procedural pain and burn pain. The Company’s products include Dyloject (injectable diclofenac), Ereska (intranasal ketamine, formerly PMI-150) and Rylomine (intranasal morphine).